Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same patented DAP technology for precise and consistent unweighting that is the cornerstone of every AlterG system. And the best part? The AlterG NEO comes at the most cost-effective pricing to date. NEO helps you deliver results for your clients at a price-point that is right for you, on an Anti-Gravity Treadmill that is right for them.

The AlterG NEO combines updated user-friendly design with trusted Anti-Gravity technology for precise and consistent unweighting in physical rehabilitation and athletic training

Updated features and a cost-effective price point make the core AlterG technology accessible for a broader range of clinics and training facilities

 

 
 

MARLBOROUGH, Mass. and FREMONT, Calif. and YOKNEAM ILLIT, Israel, June 26, 2024 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced the launch of its new AlterG NEO Anti-Gravity Treadmill. This latest innovation from Lifeward leverages the unique Differential Air Pressure (“DAP”) technology that is the cornerstone of every AlterG Anti-Gravity System and introduces it at a price point that makes the technology accessible to a broader range of physical rehabilitation clinics and athletic training facilities.

“The AlterG NEO is a shining example of how Lifeward has helped to accelerate the development of new solutions which leverage our core technologies and expand our markets,” said Larry Jasinski, CEO of Lifeward. “Our patented DAP technology has been trusted by our customers for nearly two decades to precisely and safely unweight their patients during rehabilitation and recovery, and we are thrilled to introduce the AlterG NEO so that more clinics and patients can access the benefits of Anti-Gravity rehabilitation than ever before.”

The AlterG NEO is being debuted at the National Athletic Trainers Association (“NATA”) Clinical Symposia & AT Expo June 26 and 27, 2024 in New Orleans. Attendees will have the opportunity to see the NEO’s new design and experience the new features live.

Full details about the AlterG NEO can be found at alterg.com.

About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity systems, the ReStore Exo-Suit, and the MyoCycle FES Systems.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.

ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.

Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek,” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading “Risk Factors” in the Company’s annual report on Form 10-K and 10-K/A, as amended, for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:
LifeSci Communications
E: media@golifeward.com

Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward
E: ir@golifeward.com

A photo accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/0d837098-09a5-456e-85f7-5c139adb217c

A video accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/5a83c307-ce63-4675-b526-cc17a14f27c9

Staff

Recent Posts

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

59 minutes ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

1 hour ago

Hallmark Adds Senior Executives to Enhance Customer Success and Strategic Partnerships

New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…

1 hour ago

CARESYNTAX ANNOUNCES 2024 HIGHLIGHTS

 Company Celebrates Continued Worldwide Progress Toward Data-Driven Surgery SAN FRANCISCO and BERLIN, Dec. 23, 2024…

1 hour ago

Medit Launches a Mobile App, MEDIT M, to Revolutionize Digital Dental Workflows

SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Medit has launched a mobile app, MEDIT…

1 hour ago

Nearly 50% of Young People Resolve to Quit Nicotine in 2025

EX Program by Truth Initiative Offers a Proven Path to Success WASHINGTON, Dec. 23, 2024…

1 hour ago